ライフサイエンスコーパス: facial pain

1 ion; the product was computed as an index of facial pain.

2 ilepsy and control subjects with intractable facial pain.

3 with 5 days of upper respiratory illness and facial pain.

4 for central post-stroke pain and neuropathic facial pain.

5 r antagonist that is efficacious in reducing facial pain.

6 management differ among the various forms of facial pain.

7 f more selective treatments for headache and facial pain.

8 characterized by sudden episodes of intense facial pain.

9 r antagonist that is efficacious in reducing facial pain.

10 h trigeminal stimulation triggers paroxysmal facial pain, affects defensive peripersonal space (DPPS)

11 ght-sided perimandibular swelling, recurrent facial pain and exposed necrotic bone after previous ext

12 nd an overlapping spectrum of symptoms, with facial pain and loss of smell being the most differentia

13 an with diabetes mellitus who presented with facial pain and right eye proptosis.

14 ts have small trigeminal nerves and impaired facial pain and temperature perception.

15 nial gangliogenesis that may lead to loss of facial pain and temperature sensation in FD.

16 d with CRS cases who reported smell loss and facial pain and/or pressure and had the weakest associat

17 /pressure; smell loss without pain/pressure; facial pain and/or pressure without smell loss; and both

18 Paradoxically, headache, facial pain, and sleep disturbance occurred significantl

19 ression, but the rates of burning and aching facial pain, as reported on the last follow-up questionn

20 nts, who were referred to a university-based facial pain clinic, were asked to mark all painful sites

21 ostulated that the most commonly undiagnosed facial pain conditions include neuropathic and myofascia

22 Trigeminal neuralgia (TN) is a facial pain disorder characterized by intense and paroxy

23 dache behaviors, including facial allodynia, facial pain expressions, and reduced movement, which are

24 p period, patients recorded daily ratings of facial pain intensity and duration; the product was comp

25 Facial pain is a debilitating disorder if left untreated

26 9 degrees C) and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or

27 , high fever and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or

28 interference leads to spontaneous and evoked facial pain-like behavior in freely moving rats.

29 althy male patient presented with left-sided facial pain over the prior 5 weeks.

30 that among a great percentage of persistent facial pain patients the pain distribution is more wides

31 is symptoms-especially those with unilateral facial pain-regardless of duration of illness.

32 scores (SMD, -0.96; 95% CI, -2.18 to 0.25), facial pain scores (SMD, -0.57; 95% CI, -1.68 to 0.55),

33 g" when compared with the 19% annual rate of facial pain symptoms.

34 en proven effective in numerous headache and facial pain syndromes.

35 t (up to eight a day), unilateral attacks of facial pain with associated ipsilateral autonomic featur

36 disorder characterized by intense paroxysmal facial pain within areas innervated by the trigeminal ne